Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study

Monique K van der Kooij; Arjen Joosse; Karijn P M Suijkerbuijk; Maureen J B Aarts; Franchette W P J van den Berkmortel; Christian U Blank; Marye J Boers-Sonderen; Alfonsus J M van den Eertwegh; Jan Willem B de Groot; John B A G Haanen; Geke A P Hospers; Djura Piersma; Rozemarijn S van Rijn; Astrid A M van der Veldt; Gerard Vreugdenhil; Hans M Westgeest; Michel W J M Wouters; Olaf M Dekkers; Ellen Kapiteijn

doi:10.1038/s41416-022-02088-8

Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study

Br J Cancer. 2023 Mar;128(5):707-710. doi: 10.1038/s41416-022-02088-8. Epub 2022 Dec 23.

Authors

Monique K van der Kooij¹, Arjen Joosse², Karijn P M Suijkerbuijk³, Maureen J B Aarts⁴, Franchette W P J van den Berkmortel⁵, Christian U Blank⁶, Marye J Boers-Sonderen⁷, Alfonsus J M van den Eertwegh⁸, Jan Willem B de Groot⁹, John B A G Haanen⁶, Geke A P Hospers¹⁰, Djura Piersma¹¹, Rozemarijn S van Rijn¹², Astrid A M van der Veldt², Gerard Vreugdenhil¹³, Hans M Westgeest¹⁴, Michel W J M Wouters^{15

16}, Olaf M Dekkers¹⁷, Ellen Kapiteijn¹⁸

Affiliations

¹ Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, PO box 9600, 2300 RC, Leiden, The Netherlands.
² Department of Medical Oncology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, 3000 CA, Rotterdam, The Netherlands.
³ Department of Medical Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
⁴ Department of Medical Oncology, Maastricht University Medical Center, P. Debyelaan 25, 6202 AZ, Maastricht, The Netherlands.
⁵ Department of Medical Oncology, Zuyderland Medical Center, 6130 MB, Sittard-Geleen, The Netherlands.
⁶ Department of Medical Oncology, Netherlands Cancer Institute- Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
⁷ Department of Medical Oncology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6500 HB, Nijmegen, The Netherlands.
⁸ Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, de Boelelaan 1117, 1081 HZ, Amsterdam, The Netherlands.
⁹ Isala Oncology Center, Isala, 8000 GK, Zwolle, The Netherlands.
¹⁰ Department of Medical Oncology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
¹¹ Department of Medical Oncology, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ, Enschede, The Netherlands.
¹² Department of Medical Oncology, Medical Center Leeuwarden, Henri Dunantweg 2, 8934 AD, Leeuwarden, The Netherlands.
¹³ Department of Medical Oncology, Maxima Medical Center, de Run 4600, 5500 MB, Veldhoven, The Netherlands.
¹⁴ Department of Medical Oncology, Amphia Ziekenhuis, Langendijk 175, 4819 EV, Breda, The Netherlands.
¹⁵ Dutch Institute for Clinical Auditing, Rijnsburgerweg 10, 2333 AA, Leiden, The Netherlands.
¹⁶ Department of Surgical Oncology, Netherlands Cancer Institute- Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
¹⁷ Department of Clinical Epidemiology, Leiden University Medical Center, Albinusdreef 2, PO box 9600, 2300 RC, Leiden, The Netherlands.
¹⁸ Department of Medical Oncology, Leiden University Medical Center, Albinusdreef 2, PO box 9600, 2300 RC, Leiden, The Netherlands. h.w.kapiteijn@lumc.nl.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Cohort Studies
Humans
Melanoma* / drug therapy
Nivolumab / therapeutic use
Programmed Cell Death 1 Receptor* / therapeutic use

Substances

Programmed Cell Death 1 Receptor
Nivolumab